Announced Wed, 12 Aug · 12:24 IST
Marksans Pharma Q1 FY27: PAT jumps 44% standalone, 174% consolidated
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+8.6%1-day move
₹278.95
prior close
₹303.20
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.7+1.1+1.4+1.2+8.6+20.3+18.5+17.0+17.5+15.1————
Up moveDown movePending
AI summary
Marksans Pharma Q1 FY27: Standalone PAT up 43.7% to Rs 690.37 million on nearly flat revenue of Rs 3,211.87 million. Consolidated revenue grew 35.6% to Rs 8,407.96 million, PAT surged to Rs 1,594.07 million from Rs 582.02 million. Company acquired Netherlands-based QliniQ B.V. for EUR 7.5 million and post-quarter bought German ABCnow GmbH for EUR 1.1 million. Auditor issued an unmodified opinion.
Likely market impact
Strong profit growth led by international subsidiaries and large forex gain; acquisitions expand European footprint.